IDH1 and glioblastoma: Most preclinical and clinical studies have been performed in models of isocitrate dehydrogenase (IDH)-wild type glioblastoma as defined by CNS WHO 2021 criteria, with a select few studies in grade 4 IDH-mutant astrocytoma models.